Gly-Ser-OH
Need Assistance?
  • US & Canada:
    +
  • UK: +

Gly-Ser-OH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Others
Catalog number
BAT-005033
CAS number
7361-43-5
Molecular Formula
C5H10N2O4
Molecular Weight
162.15
Gly-Ser-OH
IUPAC Name
(2S)-2-[(2-aminoacetyl)amino]-3-hydroxypropanoic acid
Synonyms
Glycyl-L-serine
Appearance
Crystalline
Purity
≥ 97% (HPLC)
Melting Point
183-192º C
Storage
Store at 2-8 °C
InChI
InChI=1S/C5H10N2O4/c6-1-4(9)7-3(2-8)5(10)11/h3,8H,1-2,6H2,(H,7,9)(H,10,11)/t3-/m0/s1
InChI Key
BCCRXDTUTZHDEU-VKHMYHEASA-N
Canonical SMILES
C(C(C(=O)O)NC(=O)CN)O
1. Isolation and identification of two learning-induced brain peptides
D F Tate, L Galvan, G Ungar Pharmacol Biochem Behav. 1976 Oct;5(4):441-8. doi: 10.1016/0091-3057(76)90108-8.
Goldfish were trained either to avoid the blue compartment of a tank and swim into the green compartment or, conversely, to avoid green and prefer blue. Preliminary experiments indicated that acquisition of the avoidance behavior was associated with the presence in the brain of two peptides, one found in blue avoiding (BA), another in green avoiding (GA) fish. With the help of behavioral bioassays, the peptides were isolated and purified, and their structure was determined by ultrasmicroanalytical techniques. The sequence of the BA peptide, pglu-ile-gly-ala-val-phe-pro-leu-lys-tyr-gly-ser-lys-OH was reproduced by synthesis. Sequential analysis of the GA peptide gave two alternative structures, NAc-lys-gly-gln-ile-ala-val-phe-pro-leu-lys-tyr-gly-ser-OH or NAc-lys-gly-ala-val-gln-ile-phe-pro-lys-tyr-gly-ser-OH, both of which are being synthetized to be compared with the natural compound. Overlapping sequences between the BA and GA peptides suggest the existence of a family of peptides associated with behavior based on color discrimination.
2. Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs
Diana Højmark Omkvist, Dennis Jespersen Trangbæk, Jemma Mildon, James S Paine, Birger Brodin, Mikael Begtrup, Carsten Uhd Nielsen Eur J Pharm Biopharm. 2011 Feb;77(2):327-31. doi: 10.1016/j.ejpb.2010.12.009. Epub 2010 Dec 13.
The intestinal di/tri-peptide transporter 1 (hPEPT1) has been suggested as a drug delivery target for peptide-based prodrugs. The aim of the study was to synthesize a series of 11 serine-containing dipeptides (H-X(aa)-Ser-OH) and to investigate the relationship between binding to and transport via hPEPT1. An additional aim was to design a dipeptide which could serve as a pro-moiety for prodrugs targeted to hPEPT1. X(aa) was chosen from the 20 proteogenic amino acids. The dipeptides were synthesized using solid phase peptide synthesis. The K(i)-values of H-X(aa)-Ser-OH dipeptides for hPEPT1 in MDCK/hPEPT1 cells ranged from 0.14 mM (logIC(50)=-0.85 ± 0.06) for H-Tyr-Ser-OH to 0.89 mM (logIC(50)=-0.09 ± 0.02) for H-Gly-Ser-OH, as measured in a competition assay with [(14)C]Gly-Sar. The dipeptides were translocated via hPEPT1 with K(m)-values in the range of 0.20 (logIC(50)=-0.69 ± 0.04) for H-Met-Ser-OH to 1.04 (logIC(50)=0.02 ± 0.04) mM for H-Gly-Ser-OH. The relationship between ligand and transportate properties indicated that the initial binding of the ligand to hPEPT1 is the major determinant for translocation of the investigated dipeptides. H-Phe-Ser-OH was selected as a pro-moiety, and two prodrugs were synthesized, i.e. H-Phe-Ser(Ibuprofyl)-OH and H-Phe-Ser(Bz)-OH. Both H-Phe-Ser(Ibuprofyl)-OH and H-Phe-Ser(Bz)-OH had high affinity for hPEPT1 with K(i)-values of 0.07 mM (logIC(50)=-0.92 ± 0.12) and 0.12 mM (logIC(50)=-1.17 ± 0.40), respectively. However, none of the prodrugs were translocated via hPEPT1. This indicated that the coupling of the drug compounds to the peptide backbone did not decrease transporter binding, but abolished translocation, and that high affinity of prodrugs does not necessarily translate into favourable permeation properties.
3. Effects of thyrotropin releasing hormone and its analogues on unconsciousness following head injury in mice
K Tanaka, N Ogawa, H Chou, A Mori, N Yanaihara Regul Pept. 1992 Mar 19;38(2):129-33. doi: 10.1016/0167-0115(92)90051-u.
We examined the effects of thyrotropin releasing hormone (TRH) and its analogues (DN-1417: gamma-butyrolactone-gamma-carbonyl-histidyl-prolinamide citrate; MK-771: L-pyro-2-aminoadipyl-histidyl-thiazolidine-4-carboxamide; TSII-37: H-Lys-Gln-His-Pro-Gly-Ser-OH) on arousal in head injured mice, an animal model of unconsciousness. TRH, DN-1417, MK-771 and TSII-37 were injected 10 min before the head injury. TRH, DN-1417 and MK-771 caused dose-dependent decreases in the time required for recovery of the righting reflex time and in the time from the head injury to the onset of spontaneous movement. TSII-37 had no effect, when compared with the control group. In terms of the minimum effective dose, TRH and DN-1417 were of similar potency, but MK-771 was about 30-fold stronger than TRH. Measurement of the cross-reactivities of these TRH analogues by radiolabeled receptor assay suggest that the structure-binding relationship is proportional to the structure-activity relationship.
Online Inquiry
Verification code
Inquiry Basket